Labetuzumab

N/A

Report date: 2026/03/23 15:45:39

Base Information

Drug NameLabetuzumab
Drug Alias NamehCEAAnti-CEA monoclonal antibody MN 14CEA-CideMonoclonal antibody MN-14IMMU-100 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonists
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSmall Cell Lung CarcinomaPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunomedics Inc
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank